Often enough, some biotech stocks propel through expectations and invite investor frenzy. This week, it happened to Longeveron LLC . Owing to the prospective treatment of hypoplastic left heart syndrome in the Phase 2 trial, the clinical-stage firm gained a 234% value boost over the week.
Simply put, this pioneering platform degrades proteins linked to many serious and rare diseases. Arvinas uses its Protac Discovery Engine platform to develop a drug pipeline in oncology, immuno-oncology, and pro-inflammatory rare diseases. Ocuphire’s retina drug pipeline is in the exploratory stage. The company has APX2009 for geographic atrophy and APX2014 as the second-generation drug for the treatment of retinal diseases such as age-related macular degeneration. Ocuphire will start ZETA-2 Phase 2/3 trials for APX3330 in early 2025.
The company, which is mainly focused on hematology and cardiovascular , filed a Marketing Authorisation Application for its LV RP-L102 to treat Fanconi anemia. On June 30th, the FDA is scheduled to respond to the company’s application for LV KRESLADI for the treatment of severe Leukocyte Adhesion deficiency-I .
Canada Canada Latest News, Canada Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: Investingcom - 🏆 450. / 53 Read more »
Source: Investingcom - 🏆 450. / 53 Read more »
Source: Investingcom - 🏆 450. / 53 Read more »
Source: Investingcom - 🏆 450. / 53 Read more »